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Bacteriophages (phage) are viruses that only infect bacteria and typically attack only a single 
bacterial strain (Fig.1). This specificity, together with the killing capacity makes them the “natural 
enemies” of bacteria. [1]  
Phage therapy involves using phages or their products as bioagents for the treatment or 
prophylaxis of bacterial infectious diseases. There are different alternatives:  
 
1. Therapy using living phages: is the “classical” version in which the phage infect the bacteria 
near the surface and kill them by internal replication and continues multiplying for as long as 
there are bacteria to infect. 
The aim of this project is to study in detail bacteriophage therapy and its particularities, breaking this 
into different types of therapy and analyze the problems to be overcome and the potential solutions 
that are possible.  
Figure 2. Bacteriolysis. (1) Adsorption and DNA injection; (2) DNA 
replication; (3) production of head and tail; (4) synthesis of lysin; (5) 
DNA packaging; (6) completion of phage; (7) disruption of the cell wall 
and release the progeny; (8) circularization of DNA; (9) integration of 
the phage DNA into the host genome.  
From [1] 
3. Utilization of phage lysin: most 
tailed phages produce 
peptidoglycan hydrolase (lysin) 
to release their  progeny at the 
final stage of multiplication.  
 
    Lysin (Fig.4) destroys the 
peptidoglycan directly exerting a 
bacteriolytic effect. It can also 
destroy the cell walls of non-
growing  bacteria.  [1] 
Figure 3. Schematic representations of 
the genetic organization of the modified 
phage Pf3R.    From [2] 
Figure 4. Attack points of phage encoded lysins on the peptidoglycan of 
gram-positive bacteria. Amidase, endopeptidase, muramidase or 
glucosaminidase may be released, depending on the cutting site.   From 
[1] 
Figure 5. Overview of potential solutions (a) The complexity of phage cocktails is limited by regulation and 
manufacturing. (b) Evolution can produce phages with enhanced properties such as decreased clearance. (c) Drug-
delivery technologies can enhance systemic phage delivery and reduce phage inactivation and clearance. (d) Enzymatic 
bacteriophages can be engineered to degrade barriers to phage adsorption (left) and disrupt the structure of bacterial 
biofilms (right). (e) Non-lytic and/or non-replicative phages can reduce the release of bacterial endotoxins. (f) 
Bacteriophages can be engineered to target intracellular defense pathways, which protect bacteria against antibiotics. 
From  [4]   
2. Problems to overcome 4. Comparing phage and antibiotics 
1. Types of bacteriophage therapy: 
Figure 7. Antibiotics have direct and 
indirect effects on the microbiota.   
From [6] Figure 6. Color enhanced Transmission Electron Micrograph (TEM) of 
T4 enterobacteria phages attacking an E. coli cell.  
 From © Eye of Science/Science Source   
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2. Phage therapy using non-replicating genetically modified 
phages: Hagens et al. constructed a recombinant phage 
Pf3R, in which the export protein gene of the genome was 
replaced with a restriction endonuclease gene (Fig. 3). The 
endonuclease digested the host genomic DNA and 
consequentially killed the bacteria with minimal release of 
endotoxin in vitro.  [2] 
4. Protein antibiotics: some small phages do not have the genes for holin or lysin proteins. 
Instead, they produce a protein that inhibits a step in murein monomer synthesis. Their inhibitory 
gene products are known as “protein antibiotics”.  [1, 3] 
 
Currently, many pathogenic bacteria have acquired multiple drug resistance. In this context, one 
intriguing approach is to use bacteriophages therapy. 
 Phages could play an important role in treating bacterial infections in humans, animals and crops, as well 
as in decontaminating food supplies and communal environments.  
However, it is also quite clear that the safe  and controlled use of phage therapy will required detailed 
information on the properties and behavior of the specific phage-bacterium system. 
3. Potential solutions: 
Figure 1. Phage T4.    From  Science Source   
1. Biology of bacteriophages: 
2. Life cycle of phages: Phages can be divided into two groups  
3. Objective: 
  Bacteriophages Antibiotics 
  
 
Environment 
 
Are the most abundant living 
entities on the planet and 
natural enemies of bacteria 
  
Normally synthetics or 
semisynthetic 
  
Host range 
  
Narrower 
Destroy all bacterial 
cells disturbing the 
normal microflora 
 
Side effects 
 
Have not been described 
 
Have severe side 
effects 
  
Concentration 
 
Decrease as soon as 
bacterial cells are eliminated 
  
Decreases with time 
Figure 2 illustrates the general mechanism of baceteriolysis by tailed phages.   
Accessibility 
 
Restriction / 
Modification  
 
 
 
 
 
 
 
Immunogenicity 
 
Resistance 
 
Phages won’t be 
successful where 
they cannot make 
contact with the 
target bacteria, or 
do so only in a 
very limited way 
(Ex. Intracellular 
bacteria) 
In order to protect 
themselves many 
types of bacteria 
have developed a 
method to chop up 
any foreign DNA  
endonuclease that 
restrict the infection 
of phages. 
In prolonged 
treatments has 
been observed a 
development of 
antibodies 
against phages. 
 
 In continued 
incubation of a 
culture lysed by 
phage, resistant 
bacteria can 
appear       
 
Lytic phage 
• Repeats a cycle in which self-
proliferation is synchronous 
with destruction of bacteria 
(lytic cycle) 
Lysogenic phage  
• Has a lysogenic cycle (the 
phage genome multiplies 
cooperatively with the host 
without destroying it) in addition 
to a lytic cycle 
